{"product_id":"3sbio-business-model-canvas","title":"3SBio Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock the strategic blueprint of a biopharma's growth and therapeutic focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the strategic blueprint behind 3SBio’s growth and therapeutic focus with this Business Model Canvas preview. It outlines customer segments, value propositions, key partners, and revenue streams to show how the company scales and sustains margins. Purchase the full, editable Canvas (Word \u0026amp; Excel) for a section-by-section analysis and actionable insights for investors, strategists, and founders.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic R\u0026amp;D alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAcademic R\u0026amp;D alliances with universities and institutes accelerate discovery in oncology, nephrology and immunology by supplying disease biology, target validation and translational models; joint grants and peer‑reviewed publications de‑risk early science and broaden pipeline options, while clear IP frameworks establish ownership and option rights to enable downstream licensing and co‑development.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical sites \u0026amp; KOL networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHospital networks and KOL networks accelerate patient enrollment and bolster trial credibility, with NMPA emphasis on real-world evidence expanded in 2024 driving closer hospital-regulator alignment. KOLs shape protocol design and endpoints to match standards of care, while advisory boards guide label strategy and market access. Co-authored clinical data consistently increases clinician confidence and adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCRO\/CMO and technology vendors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSpecialized CROs streamline preclinical, clinical ops and biometrics, with the global CRO market estimated at ~$64 billion in 2024, accelerating time-to-clinic and reducing fixed headcount. CMOs provide surge biologics, fill-finish and QC capacity—outsourcing now represents about 40% of global biologics manufacturing in 2024. Platform vendors supply single-use systems (\u0026gt;60% adoption), advanced bioanalytics and digital QMS, improving speed, quality and cost flexibility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistribution and market access partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSpecialty distributors expand 3SBios reach into hospital pharmacies and regional tenders, supporting penetration in over 2,000 tertiary and secondary hospitals across China in 2024 and boosting hospital formulary listings.\u003c\/p\u003e\n\u003cp\u003eMarket access consultants prepared HTA dossiers and price negotiations in 2024, contributing to faster NRDL and provincial reimbursement entries; pharmacoeconomic collaborators produced cost-effectiveness models that improved payer acceptance rates by double digits.\u003c\/p\u003e\n\u003cp\u003eTogether these partners increased formulary wins and product availability, translating into measurable uplift in hospital sales and tender success during 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDistribution: coverage \u0026gt;2,000 hospitals (2024)\u003c\/li\u003e\n\u003cli\u003eMarket access: HTA dossiers driving NRDL\/provincial listings (2024)\u003c\/li\u003e\n\u003cli\u003ePharmacoeconomics: cost-effectiveness evidence improving payer approvals\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing and co-development partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn-licensing complements 3SBio’s internal pipeline with differentiated assets while out-licensing monetizes non-core geographies and indications; co-development deals share pivotal study costs and risk, with milestones and royalties providing diversified revenue streams. Royalty rates typically range mid-single to low-double digits; recent partnerships have accelerated late-stage portfolio expansion in 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIn-licensing: fills pipeline gaps\u003c\/li\u003e\n\u003cli\u003eOut-licensing: monetizes non-core markets\u003c\/li\u003e\n\u003cli\u003eCo-dev: shares cost\/risk\u003c\/li\u003e\n\u003cli\u003eMilestones\/royalties: diversify revenue (mid-single to low-double digit royalties)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic R\u0026amp;D to market: \u0026gt;2,000 hospitals, ~$64B CRO, ~40% biologics outsourced\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003e3SBio leverages academic R\u0026amp;D, hospital\/KOL networks, CROs\/CMOs and specialty distributors to accelerate discovery, trials and market access; 2024 KPIs include \u0026gt;2,000 hospital coverage, CRO market ~$64B and ~40% biologics outsourced. In-licensing and co-dev deals fill pipelines and de-risk costs, with royalties mid-single to low-double digits.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003e2024 Metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\/distribution\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;2,000 hospitals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRO market\u003c\/td\u003e\n\u003ctd\u003e~$64B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiologics outsourcing\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSingle-use systems\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60% adoption\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties\u003c\/td\u003e\n\u003ctd\u003emid-single to low-double %\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive Business Model Canvas tailored to 3SBio, detailing customer segments, value propositions, channels, revenue streams and cost structure across the 9 BMC blocks; includes competitive advantages, SWOT-linked insights and investor-ready narrative for strategic decisions and funding discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses 3SBio’s biotech and specialty-pharma strategy into a one-page, editable canvas to speed due diligence and align stakeholders; ideal for quick comparisons, board briefings, and collaborative updates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiologic R\u0026amp;D and pipeline management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDiscovery, lead optimization and candidate selection drive 3SBios pipeline flow, with 2024 efforts focused on accelerating IND-enabling studies. Biomarker and mechanism studies in 2024 sharpen patient selection to improve trial readouts and attrition rates. Regular portfolio reviews balance risk across modalities and stages, reallocating resources toward high-value assets. Aggressive IP filing in 2024 protects future commercial value and licensing opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical development and medical affairs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDesigning and running Phase I–III trials generates registration-grade evidence; industry averages show ~10% overall approval probability from Phase I and mean development time ~10–12 years with estimated total cost around $2.6 billion (widely cited 2020–2024 estimates).\u003c\/p\u003e\n\u003cp\u003eMedical affairs publishes and presents data at major congresses and CME programs, often supporting \u0026gt;100 abstracts per year across global oncology and biologics portfolios.\u003c\/p\u003e\n\u003cp\u003eInvestigator-initiated studies extend insights into real-world settings, complementing randomized data with larger observational cohorts and registry analyses.\u003c\/p\u003e\n\u003cp\u003ePost-approval studies and real-world evidence programs drive label expansions and market access, frequently underpinning supplementary approvals and payer negotiations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGMP manufacturing of biologics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGMP manufacturing at 3SBio integrates upstream cell culture (typical fed‑batch mAb yields 1–5 g\/L) and downstream purification with recoveries around 60–80% to ensure consistent quality. Process validation and comparability are performed per ICH Q5E\/Q6B to sustain regulatory compliance. Fill‑finish and cold‑chain logistics (storage ranges from −80°C to 2–8°C) protect product integrity. Continuous improvement programs target COGS reductions in the order of ~10–20% over time.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and pharmacovigilance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePreparation of CTAs, NDAs\/BLAs and lifecycle submissions is core, following PDUFA review timelines (standard BLA 10 months, priority 6 months) and ICH dossier formats. Safety monitoring aggregates signals from trials and commercial use via spontaneous reports and periodic analyses. Risk management plans and PSURs (initial 6-month cadence then annual per ICH) maintain compliance; proactive agency interactions keep pathways predictable.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCTAs\/NDAs\/BLAs: regulatory dossier readiness\u003c\/li\u003e\n\u003cli\u003eSafety: trial + post-market signal capture\u003c\/li\u003e\n\u003cli\u003eRMP\/PSUR: 6-month then annual\u003c\/li\u003e\n\u003cli\u003eAgency engagement: predictable timelines (PDUFA 10\/6 mo)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization and market access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTendering and competitive pricing secure hospital inclusion and formulary placement, while health-economics dossiers quantify cost-effectiveness for payers; patient-support initiatives target adherence in China’s ~1.41 billion population (2024 est.).\u003c\/p\u003e\n\u003cp\u003eKey-account managers focus uptake in priority centers and provincial hospitals, and patient-support programs reduce access barriers through copay assistance, education and logistics coordination.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTendering: formulary access\u003c\/li\u003e\n\u003cli\u003eHealth economics: HEOR dossiers\u003c\/li\u003e\n\u003cli\u003eKey accounts: priority centers\u003c\/li\u003e\n\u003cli\u003ePatient support: adherence \u0026amp; access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e2024 IND push: \u003cstrong\u003e12+\u003c\/strong\u003e programs, \u003cstrong\u003e~10%\u003c\/strong\u003e approval\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDiscovery to IND with 2024 focus on IND-enabling studies; portfolio reviews reallocate resources across 12+ programs. Clinical development runs Phase I–III (industry approval ~10%, avg timeline 10–12 yrs). GMP yields 1–5 g\/L, recoveries 60–80%; COGS reductions target 10–20%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrograms\u003c\/td\u003e\n\u003ctd\u003e12+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproval rate\u003c\/td\u003e\n\u003ctd\u003e~10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYield\u003c\/td\u003e\n\u003ctd\u003e1–5 g\/L\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the exact 3SBio Business Model Canvas you will receive after purchase, not a mockup. Upon completing your order you'll get the full, editable file formatted as shown—ready for presentation, editing and sharing in Word and Excel formats. No surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56162320875897,"sku":"3sbio-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/3sbio-business-model-canvas.png?v=1762698911","url":"https:\/\/portersfiveforce.com\/products\/3sbio-business-model-canvas","provider":"Porter's Five Forces","version":"1.0","type":"link"}